Breast Cancer Clinical Trials

Showing 121-140 of 4,817 trials

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

NCT07524855

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

Metastatic Breast Cancer

Halda Therapeutics OpCo, Inc.33 participantsStarted Mar 2026

Sarasota, Florida, United States • Nashville, Tennessee, United States • Fairfax, Virginia, United States

RECRUITINGPhase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Iambic Therapeutics, Inc383 participantsStarted Mar 2024

La Jolla, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +45 more locations

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Related Searches

Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Dance Study for Post-surgical Pain in Breast Cancer Survivors

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Evolution of Clinical and Motivational Constructs During the Physical Activity Program KHEOPS, Already Offered to Patients at the Centre Léon Bérard

Evaluation of Safety and Performance of Intraoperative Detection of Light Signals During Electrosurgical Breast Cancer Resection

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy